Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

94
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
94
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.7K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

516
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
516
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

69
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
69
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.8K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

540
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
540

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Brain-Penetrant Nurr1 Agonist Tool.

ChemMedChem·2026
Same author

An Activator of Tailless' Repressor Function Stimulates Anti-Neurodegenerative Gene Expression.

Journal of medicinal chemistry·2026
Same author

Enhanced Intramuscular mRNA Activity of Peptide-Lipid Nanoparticles with Hydrophobized Head Groups.

Bioconjugate chemistry·2026
Same author

An Agonist/Antagonist Photo-Switchable Vitamin D Mimetic Enables Bidirectional Optical Control of VDR.

Angewandte Chemie (International ed. in English)·2026
Same author

Structural optimization of drug molecules with incrementally trained language models.

Nature communications·2026
Same author

Renal hemodynamics underlie hepatorenal physiology in bile duct-ligated rats.

Clinical science (London, England : 1979)·2026

Related Experiment Video

Updated: Sep 28, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

903

Multi-Target Drugs for Kidney Diseases.

John D Imig1, Daniel Merk2, Eugen Proschak2

  • 1Drug Discovery Center and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin.

Kidney360
|April 4, 2022
PubMed
Summary

Multi-target drugs show promise for complex kidney diseases like acute kidney injury (AKI) and chronic kidney disease (CKD). These innovative therapies target multiple pathways, offering new hope for patients.

Keywords:
basic sciencechronic kidney diseasediabetesdrug delivery systemseicosanoidsfatty acidshypertensionkidney diseasesmulti-ligand drugsnephro-pharmacologypharmaceutical preparationstranscription factors

More Related Videos

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.6K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.2K

Related Experiment Videos

Last Updated: Sep 28, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

903
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.6K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.2K

Area of Science:

  • Nephrology
  • Pharmacology
  • Computational Drug Design

Background:

  • Kidney diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), and glomerulonephritis (GN), present complex pathologies involving diverse cell types and signaling pathways.
  • These intricate conditions often necessitate therapeutics capable of addressing multiple molecular targets simultaneously.

Purpose of the Study:

  • To review the advancements and potential of multi-target drugs in treating complex kidney diseases.
  • To highlight the role of in silico drug design in accelerating the development of such therapeutics.

Main Methods:

  • Review of recent literature on multi-target drug development for kidney diseases.
  • Analysis of computational (in silico) drug design strategies enabling multi-target approaches.
  • Examination of drug mechanisms targeting inflammation, fibrosis, and metabolic dysfunction in renal pathologies.

Main Results:

  • In silico drug design has significantly advanced the development of multi-target drugs over the past decade.
  • Successful multi-target drugs have been developed for inflammatory, fibrotic, and metabolic diseases, with demonstrated potential in diabetic nephropathy and fibrotic kidney disease.
  • These drugs effectively reduce renal TGF-β signaling, inflammation, mitochondrial dysfunction, and oxidative stress.

Conclusions:

  • Multi-target drugs offer a promising therapeutic strategy for complex kidney diseases due to their ability to act on multiple cell types and signaling pathways.
  • Further research and clinical testing are warranted for recently developed multi-target drugs to fully assess their efficacy in combating kidney diseases.